Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016 (2016), Article ID 7351985, 8 pages
http://dx.doi.org/10.1155/2016/7351985
Review Article

Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson’s Disease

Department of Cell Biochemistry, University of Groningen, Nijenborgh 7, 9747 AG Groningen, Netherlands

Received 24 December 2015; Accepted 19 April 2016

Academic Editor: José Manuel Bravo-San Pedro

Copyright © 2016 Katharina E. Rosenbusch and Arjan Kortholt. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. G. Goetz, “The history of Parkinson's disease: early clinical descriptions and neurological therapies,” Cold Spring Harbor Perspectives in Medicine, vol. 1, no. 1, Article ID a008862, 2011. View at Google Scholar · View at Scopus
  2. J. C. Dächsel and M. J. Farrer, “LRRK2 and Parkinson disease,” Archives of Neurology, vol. 67, no. 5, pp. 542–547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. J. Lees, J. Hardy, and T. Revesz, “Parkinson's disease,” The Lancet, vol. 373, no. 9680, pp. 2055–2066, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. W. P. Gilks, P. M. Abou-Sleiman, S. Gandhi et al., “A common LRRK2 mutation in idiopathic Parkinson's disease,” The Lancet, vol. 365, no. 9457, pp. 415–416, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Klein and A. Westenberger, “Genetics of Parkinson's disease,” Cold Spring Harbor Perspectives in Medicine, vol. 2, Article ID a008888, 2012. View at Google Scholar · View at Scopus
  6. I. Marín, W. N. van Egmond, and P. J. M. van Haastert, “The Roco protein family: a functional perspective,” The FASEB Journal, vol. 22, no. 9, pp. 3103–3110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. W. N. van Egmond and P. J. M. van Haastert, “Characterization of the Roco protein family in Dictyostelium discoideum,” Eukaryotic Cell, vol. 9, no. 5, pp. 751–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Bosgraaf and P. J. M. Van Haastert, “Roc, a Ras/GTPase domain in complex proteins,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1643, no. 1–3, pp. 5–10, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Deng, W. Le, Y. Guo et al., “Genetic analysis of LRRK2 mutations in patients with Parkinson disease,” Journal of the Neurological Sciences, vol. 251, no. 1-2, pp. 102–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Trabzuni, M. Ryten, W. Emmett et al., “Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus,” PLoS ONE, vol. 8, no. 8, Article ID e70724, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Bonifati, “Parkinsonism and related disorders genetics of Parkinson's disease—state of the art, 2013,” Parkinsonism & Related Disorders, vol. 20, pp. S23–S28, 2014. View at Google Scholar
  12. B. Thomas and M. F. Beal, “Parkinson's disease,” Human Molecular Genetics, vol. 16, no. 2, pp. R183–R194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Zimprich, S. Biskup, P. Leitner et al., “Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology,” Neuron, vol. 44, no. 4, pp. 601–607, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Li, D. Yang, S. Zhong et al., “Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models,” Human Molecular Genetics, vol. 23, no. 23, pp. 6212–6222, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Greggio, S. Jain, A. Kingsbury et al., “Kinase activity is required for the toxic effects of mutant LRRK2/dardarin,” Neurobiology of Disease, vol. 23, no. 2, pp. 329–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. V. S. Anand and S. P. Braithwaite, “LRRK2 in Parkinson's disease: biochemical functions,” FEBS Journal, vol. 276, no. 22, pp. 6428–6435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. R. Cookson, “The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease,” Nature Reviews Neuroscience, vol. 11, no. 12, pp. 791–797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. R. Esteves, R. H. Swerdlow, and S. M. Cardoso, “LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis,” Experimental Neurology, vol. 261, pp. 206–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. R. D. Mills, T. D. Mulhern, F. Liu, J. G. Culvenor, and H.-C. Cheng, “Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2),” Human Mutation, vol. 35, no. 4, pp. 395–412, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Biosa, A. Trancikova, L. Civiero et al., “GTPase activity regulates kinase activity and cellular phenotypes of parkinson's disease-associated LRRK2,” Human Molecular Genetics, vol. 22, no. 6, pp. 1140–1156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Stafa, A. Trancikova, P. J. Webber, L. Glauser, A. B. West, and D. J. Moore, “GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1,” PLoS Genetics, vol. 8, no. 2, Article ID e1002526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Xiong, C. E. Coombes, A. Kilaru et al., “GTPase activity plays a key role in the pathobiology of LRRK2,” PLoS Genetics, vol. 6, no. 4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Ito, T. Okai, G. Fujino et al., “GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease,” Biochemistry, vol. 46, no. 5, pp. 1380–1388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. B. West, D. J. Moore, C. Choi et al., “Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity,” Human Molecular Genetics, vol. 16, no. 2, pp. 223–232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. I. R. Vetter and A. Wittinghofer, “The guanine nucleotide-binding switch in three dimensions,” Science, vol. 294, no. 5545, pp. 1299–1304, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-M. Taymans, R. Vancraenenbroeck, P. Ollikainen et al., “LRRK2 kinase activity is dependent on LRRK2 gtp binding capacity but independent of LRRK2 GTP binding,” PLoS ONE, vol. 6, no. 8, Article ID e23207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. W. W. Smith, Z. Pei, H. Jiang, V. L. Dawson, T. M. Dawson, and C. A. Ross, “Kinase activity of mutant LRRK2 mediates neuronal toxicity,” Nature Neuroscience, vol. 9, no. 10, pp. 1231–1233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. N. G. James, M. A. Digman, E. Gratton et al., “Number and brightness analysis of LRRK2 oligomerization in live cells,” Biophysical Journal, vol. 102, no. 11, pp. L41–L43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Schapansky, J. D. Nardozzi, F. Felizia, and M. J. LaVoie, “Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy,” Human Molecular Genetics, vol. 23, no. 16, Article ID ddu138, pp. 4201–4214, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. P. J. Webber, A. D. Smith, S. Sen, M. B. Renfrow, J. A. Mobley, and A. B. West, “Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities,” Journal of Molecular Biology, vol. 412, no. 1, pp. 94–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Berger, K. A. Smith, and M. J. Lavoie, “Membrane localization of LRRK2 is associated with increased formation of the highly active lrrk2 dimer and changes in its phosphorylation,” Biochemistry, vol. 49, no. 26, pp. 5511–5523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Greggio, I. Zambrano, A. Kaganovich et al., “The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation,” The Journal of Biological Chemistry, vol. 283, no. 24, pp. 16906–16914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Sen, P. J. Webber, and A. B. West, “Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization,” The Journal of Biological Chemistry, vol. 284, no. 52, pp. 36346–36356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. R. J. Nichols, N. Dzamko, N. A. Morrice et al., “14-3-3 Binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization,” Biochemical Journal, vol. 430, no. 3, pp. 393–404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Gotthardt, M. Weyand, A. Kortholt, P. J. M. Van Haastert, and A. Wittinghofer, “Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase,” The EMBO Journal, vol. 27, no. 16, pp. 2239–2249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Greggio, J.-M. Taymans, E. Y. Zhen et al., “The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites,” Biochemical and Biophysical Research Communications, vol. 389, no. 3, pp. 449–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Deng, P. A. Lewis, E. Greggio, E. Sluch, A. Beilina, and M. R. Cookson, “Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1499–1504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Liao, C.-X. Wu, C. Burlak et al., “Parkinson disease-associated mutation R1441H in LRRK2 prolongs the ‘active state’ of its GTPase domain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 11, pp. 4055–4060, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Iaccarino, C. Crosio, C. Vitale, G. Sanna, M. T. Carrì, and P. Barone, “Apoptotic mechanisms in mutant LRRK2-mediated cell death,” Human Molecular Genetics, vol. 16, no. 11, pp. 1319–1326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. N. D. Jorgensen, Y. Peng, C. C.-Y. Ho et al., “The WD40 domain is required for LRRK2 neurotoxicity,” PLoS ONE, vol. 4, no. 12, Article ID e8463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Reynolds, E. A. Doggett, S. M. Riddle, C. S. Lebakken, and R. J. Nichols, “LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status,” Frontiers in Molecular Neuroscience, vol. 7, article 54, 2014. View at Publisher · View at Google Scholar
  42. P. Novick and M. Zerial, “The diversity of Rab proteins in vesicle transport,” Current Opinion in Cell Biology, vol. 9, no. 4, pp. 496–504, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Beilina, I. N. Rudenko, A. Kaganovich et al., “Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 7, pp. 2626–2631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Steger, F. Tonelli, G. Ito et al., “Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases,” eLife, vol. 5, Article ID e12813, 28 pages, 2016. View at Publisher · View at Google Scholar
  45. P. Gómez-Suaga, P. Rivero-Ríos, E. Fdez et al., “LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity,” Human Molecular Genetics, vol. 23, no. 25, pp. 6779–6796, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. M. W. Dodson, T. Zhang, C. Jiang, S. Chen, and M. Guo, “Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning,” Human Molecular Genetics, vol. 21, no. 6, pp. 1350–1363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Waschbüsch, H. Michels, S. Strassheim et al., “LRRK2 transport is regulated by its novel interacting partner Rab32,” PLoS ONE, vol. 9, no. 10, Article ID e111632, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Biskup, D. J. Moore, F. Celsi et al., “Localization of LRRK2 to membranous and vesicular structures in mammalian brain,” Annals of Neurology, vol. 60, no. 5, pp. 557–569, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. A. H. V. Schapira, J. M. Cooper, D. Dexter, J. B. Clark, P. Jenner, and C. D. Marsden, “Mitochondrial complex I deficiency in Parkinson's disease,” Journal of Neurochemistry, vol. 54, no. 3, pp. 823–827, 1990. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Mortiboys, K. K. Johansen, J. O. Aasly, and O. Bandmann, “Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2,” Neurology, vol. 75, no. 22, pp. 2017–2020, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. B. West, D. J. Moore, S. Biskup et al., “Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 46, pp. 16842–16847, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Bénit, S. Lebon, M. Chol, I. Giurgea, A. Rötig, and P. Rustin, “Mitochondrial complex I deficiency in humans,” Current Genomics, vol. 5, no. 2, pp. 137–146, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. M. T. Lin and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” Nature, vol. 443, no. 7113, pp. 787–795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Niu, M. Yu, C. Wang, and Z. Xu, “Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via dynamin-like protein,” Journal of Neurochemistry, vol. 122, no. 3, pp. 650–658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Alegre-Abarrategui, H. Christian, M. M. P. Lufino et al., “LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model,” Human Molecular Genetics, vol. 18, no. 21, pp. 4022–4034, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. S. V. Sambasivarao, “Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells,” Journal of Neurochemistry, vol. 18, pp. 1199–1216, 2013. View at Google Scholar
  57. T. D. Papkovskaia, K.-Y. Chau, F. Inesta-Vaquera et al., “G2019s leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization,” Human Molecular Genetics, vol. 21, no. 19, pp. 4201–4213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Gómez-Suaga, B. Luzón-Toro, D. Churamani et al., “Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP,” Human Molecular Genetics, vol. 21, no. 3, Article ID ddr481, pp. 511–525, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. J. M. Bravo-San Pedro, M. Niso-Santano, R. Gómez-Sánchez et al., “The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway,” Cellular and Molecular Life Sciences, vol. 70, no. 1, pp. 121–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. Y.-C. Su, X. Guo, and X. Qi, “Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1852, no. 1, pp. 12–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Hang, J. Thundyil, and K.-L. Lim, “Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection,” Annals of the New York Academy of Sciences, vol. 1350, pp. 37–47, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Vande Walle, M. Lamkanfi, and P. Vandenabeele, “The mitochondrial serine protease HtrA2/Omi: an overview,” Cell Death and Differentiation, vol. 15, no. 3, pp. 453–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Deng, M. W. Dodson, H. Huang, and M. Guo, “The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14503–14508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Venderova, G. Kabbach, E. Abdel-Messih et al., “Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease,” Human Molecular Genetics, vol. 18, no. 22, pp. 4390–4404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. X. Lin, L. Parisiadou, X.-L. Gu et al., “Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant α-synuclein,” Neuron, vol. 64, no. 6, pp. 807–827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. I. Irrcher, H. Aleyasin, E. L. Seifert et al., “Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics,” Human Molecular Genetics, vol. 19, no. 19, pp. 3734–3746, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. K. J. Thomas, M. K. McCoy, J. Blackinton et al., “DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy,” Human Molecular Genetics, vol. 20, no. 1, pp. 40–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Cohen, “Protein kinases—the major drug targets of the twenty-first century?” Nature Reviews Drug Discovery, vol. 1, no. 4, pp. 309–315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. A. D. Reith, P. Bamborough, K. Jandu et al., “GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 17, pp. 5625–5629, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Ramsden, J. Perrin, Z. Ren et al., “Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons,” ACS Chemical Biology, vol. 6, no. 10, pp. 1021–1028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. H. G. Choi, J. Zhang, X. Deng et al., “Brain penetrant LRRK2 inhibitor,” ACS Medicinal Chemistry Letters, vol. 3, no. 8, pp. 658–662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. X. Deng, N. Dzamko, A. Prescott et al., “Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2,” Nature Chemical Biology, vol. 7, no. 4, pp. 203–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. B. K. Gilsbach, A. C. Messias, G. Ito et al., “Structural characterization of LRRK2 inhibitors,” Journal of Medicinal Chemistry, vol. 58, no. 9, pp. 3751–3756, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. X. Deng, H. G. Choi, S. J. Buhrlage, and N. S. Gray, “Leucine-rich repeat kinase 2 inhibitors: a patent review (2006–2011),” Expert Opinion on Therapeutic Patents, vol. 22, no. 12, pp. 1415–1426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. A. A. Estrada and Z. K. Sweeney, “Chemical biology of leucine-rich repeat kinase 2 (LRRK2) inhibitors,” Journal of Medicinal Chemistry, vol. 58, no. 17, pp. 6733–6746, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. R. N. Fuji, M. Flagella, M. Baca et al., “Effect of selective LRRK2 kinase inhibition on nonhuman primate lung,” Science Translational Medicine, vol. 7, no. 273, Article ID 273ra15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Jaleel, R. J. Nichols, M. Deak et al., “LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity,” Biochemical Journal, vol. 405, no. 2, pp. 307–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. J.-M. Taymans, “The GTPase function of LRRK2,” Biochemical Society Transactions, vol. 40, no. 5, pp. 1063–1069, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. P. A. Lewis, E. Greggio, A. Beilina, S. Jain, A. Baker, and M. R. Cookson, “The R1441C mutation of LRRK2 disrupts GTP hydrolysis,” Biochemical and Biophysical Research Communications, vol. 357, no. 3, pp. 668–671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. X. Li, Y.-C. Tan, S. Poulose, C. W. Olanow, X.-Y. Huang, and Z. Yue, “Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants,” Journal of Neurochemistry, vol. 103, no. 1, pp. 238–247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Li, X. He, J. M. Thomas et al., “A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models,” PLoS ONE, vol. 10, no. 3, Article ID e0122461, pp. 1–15, 2015. View at Publisher · View at Google Scholar · View at Scopus